Kidney research (APOL1 and FSGS) violates new ethics of 'race': Medicontextualism debunks bad science undermining healthcare

For decades, the medical world has operated under a specific assumption: that the color of a person's skin is a reliable biological map to their health. This idea suggested that genes linked to ancestry, particularly those common in people with West African heritage, were the primary drivers of certain kidney diseases. Consequently, doctors and researchers often used a person's self-identified race as a shortcut to predict risk, adjust treatment dosages, or explain why some groups suffered more than others. The logic was that biology, not environment, was the root cause. However, this approach has left a confusing gap in understanding. If biology were the sole culprit, why do kidney failure rates vary wildly between cities in the same country, and why do people with similar genetic backgrounds have vastly different health outcomes depending on where they live? The question at the heart of this new research is whether the focus on genes has blinded scientists to the real, physical forces shaping health: the conditions of daily life, the quality of neighborhoods, and the history of how society treats different groups of people.

A team of researchers from Brown University Health has taken a fresh look at this problem, proposing a new way to think about the connection between race and kidney disease. They call their approach "medicontextualism," a term that simply means looking at the medical story within the full context of a person's life. Instead of asking if a gene causes a disease, they ask how the environment surrounding that gene might be the true cause. To test this, they turned to a unique group of people: United States military veterans. Unlike the general population, where Black and White Americans often live in vastly different neighborhoods with different access to food, education, and healthcare, veterans share a common starting point. They all passed the same physical and educational standards to join the service, they all received the same training, and they all have access to the same healthcare system through the Veterans Administration. By comparing Black and White veterans, the researchers created a scenario where the social playing field was much more level.

When the team examined kidney failure rates among these veterans, the results were striking. In the general population, Black Americans are significantly more likely to develop kidney failure than White Americans. But among the veterans, once the researchers removed a specific mathematical adjustment that had been used for years to account for race, the gap disappeared. The data showed that under these more equal conditions, Black and White veterans had nearly identical risks for kidney failure. This finding suggests that the disparity seen in the wider world is not an inevitable result of biology or genetics, but rather a reflection of the unequal social conditions that exist outside the military. The researchers argue that the "race correction" used in medical formulas has been masking the true picture, creating an illusion that biological differences are driving the problem when, in fact, social inequality is the engine.

The study also re-examined the role of a specific gene called APOL1, which has been heavily studied for its link to kidney disease in people of West African descent. For years, the presence of two copies of a high-risk version of this gene was thought to be a major cause of kidney failure in Black patients. The researchers dug into data from thousands of veterans to see if this gene was the smoking gun. They found that while the gene does carry some risk, its effect is far smaller than previously believed when compared to other factors. When they looked at patients who were critically ill with COVID-19, the factors that actually predicted kidney injury were things like the need for a breathing machine or strong blood-pressure drugs, not the genetic makeup of the patient. The gene appeared to be a minor player in a story dominated by how sick the patient was and how well they were treated. The researchers suggest that the gene might be acting as a marker for something else entirely: the physical appearance that leads to discrimination. In a society where skin color determines how people are treated, the gene becomes a proxy for the stress and deprivation caused by racism, rather than the direct cause of the disease itself.

The paper challenges the idea that we can simply fix kidney disease by finding the right genetic target or developing a new drug for a specific "racial" group. Instead, it points to a broader, more uncomfortable truth. The disparities in kidney health are not a biological inevitability but a consequence of structural racism. The researchers highlight that factors like lead exposure in old housing, lack of access to quality education, and the stress of living in segregated neighborhoods are the real drivers of poor health. These environmental and social forces, which they call the "medicontext," are what shape the body over a lifetime. The study notes that in places like North Carolina, where kidney failure rates are highest, the problem is not just about genes but about the history of segregation and the ongoing reality of unequal resources. The researchers argue that continuing to treat race as a biological category in medicine is a form of bad science that distracts from these root causes.

Ultimately, the paper calls for a shift in how medical research is conducted and how doctors think about their patients. It suggests that the focus should move away from trying to categorize people by race and toward measuring the actual conditions of their lives. The researchers propose that if we want to understand why some people get sick and others do not, we must look at the environment, the economy, and the history of discrimination that surrounds them. They argue that the current system, which often relies on race as a shortcut, is flawed and potentially harmful because it ignores the real reasons for health disparities. By looking at the data through the lens of social context rather than biology, the study offers a clearer path forward: one where the goal is to create equal conditions for everyone, rather than accepting unequal outcomes as natural. The work does not claim to have solved the problem of kidney disease, but it does provide a powerful argument that the solution lies not in our genes, but in how we build our society.